# Thomas Arnold

> Thomas (Tom) Arnold is the Chief Executive Officer of ViCentra, the Dutch maker of Kaleido, billed as one of the smallest, lightest and most precise insulin patch pumps in its class. Appointed in February 2025 after nearly 25 years across Medtronic, PROCEPT BioRobotics, Boston Scientific and Sorin Group, he is steering ViCentra's smartphone-controlled automated insulin delivery system into European markets and toward a US entry, backed by financing that has grown from $85M to $98M.

- **Role:** Chief Executive Officer at ViCentra (Kaleido)
- **Organizations:** ViCentra, Kaleido, Medtronic, PROCEPT BioRobotics, Boston Scientific, Sorin Group
- **Nationality:** American
- **Known for:** Appointed CEO of ViCentra in February 2025 after nearly 25 years in medtech and diabetes leadership, Helped launch the world's first hybrid closed-loop insulin pump system during 7+ years at Medtronic, Led ViCentra through funding growth from $85M to $98M to scale manufacturing and expand market access

## Career timeline

- **~2000s** — Began a medtech and diabetes leadership career spanning nearly 25 years
- **Sorin Group** — Held a leadership role at the cardiac and medical device company
- **Boston Scientific** — Held a leadership role at the global medical device maker
- **Medtronic** — Spent 7+ years, serving as VP of commercial strategy and enablement; helped launch the world's first hybrid closed-loop insulin pump system
- **PROCEPT BioRobotics** — Served as VP of global marketing
- **2025-02** — Appointed Chief Executive Officer of ViCentra (announced February 26, 2025)
- **2025-09** — ViCentra raised $85M (Series D) to scale Kaleido manufacturing and accelerate market penetration
- **2026-05** — ViCentra announced commercial launch of its smartphone-controlled Kaleido automated insulin delivery system, unveiled at the 60th DDG Diabetes Congress in Berlin
- **2026** — Financing expanded to $98M to accelerate European commercialization and ready the next-generation system for US access

## Achievements

- Appointed CEO of ViCentra in February 2025 after nearly 25 years in medtech and diabetes leadership
- Helped launch the world's first hybrid closed-loop insulin pump system during 7+ years at Medtronic
- Led ViCentra through funding growth from $85M to $98M to scale manufacturing and expand market access
- Oversaw the commercial launch of a smartphone-controlled automated insulin delivery system pairing Kaleido with Diabeloop's DBLG2 algorithm and Dexcom G7 CGM

## Latest updates

- **2026-05** — ViCentra unveiled its new smartphone-controlled Kaleido AID system at the 60th DDG Diabetes Congress in Berlin, with first commercial deliveries planned in Germany and the Netherlands for summer 2026.
- **2025-09** — ViCentra raised $85M (Series D) to scale Kaleido manufacturing; financing later expanded to $98M.

## Links

- Website: https://hellokaleido.com
- LinkedIn: http://www.linkedin.com/in/tomarnold-meddevice
- Twitter/X: https://twitter.com/HeyKaleido
- Facebook: https://facebook.com/HeyKaleido

---

Profile page: https://yespress.io/thomas-arnold
Published by YesPress — https://yespress.io
Last updated: 2026-06-04